Edgewise Therapeutics, Inc.
EWTX
Hisse Senetlerindeki Sıralama
#4054
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Hisse Fiyatı
$37.15
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$4.00B
Değişim (1 gün)
-2.75%
Değişim (1 yıl)
146.68%
Ülke
US
Ticaret Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Edgewise Therapeutics, Inc. (EWTX) için EPS
June 2026 itibariyle EPS TTM: $-1.85
Edgewise Therapeutics, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-1.85'dir. 2023 yılı sonunda, şirketin EPS'si $-1.57 idi; bu, 2022 yılındaki EPS olan $-1.26 ile önceki yıla göre artış.
Edgewise Therapeutics, Inc. için 2019 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
